Latest biopharmaceuticals Stories

SAN DIEGO and INGELHEIM, Germany, Feb. 15, 2011 /PRNewswire/ -- Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology(TM) platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement. It provides Boehringer Ingelheim with non-exclusive access to the Pfenex Expression Technology. Under...

DALLAS, February 1, 2011 /PRNewswire/ -- - Biopharmaceutical Market Worldwide is Set for High Growth. The US biopharmaceutical market which has previously contributed 60% of world market share will witness a sudden growth spurt, triggered by a spate of policy changes, grants and the recent Health Care Reform Bill and AARC. However, as the rest of the world (ROW) markets are also set for high growth and hence the overall contribution of US market share in the world market...

BALTIMORE, Jan. 5, 2010 /PRNewswire/ -- Gliknik Inc., a biopharmaceuticals company creating new cancer and immune disorder therapies, today announced an equity financing completed at a premium price. In the past seven months the company has raised $3.5 million in equity financing. Gliknik expects to use the funds to initiate a clinical program in autoimmune diseases for its lead recombinant candidate from its first-in-class stradomer(TM) platform. "An infusion of investor funding...

DALLAS, December 2, 2010 /PRNewswire/ -- BIOPHARMA analyzes the U.S. Biopharmaceuticals Market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. The report also analyses the current trends and focus of the U.S. biopharmaceutical market and the challenges faced by the industry. It also provides profiles of the major companies participating in the United States market. Browse market data tables and in-depth TOC on BIOPHARMA...

ORANGE COUNTY, Calif., Aug. 16 /PRNewswire/ -- NanoSmart(TM) Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology. "We have taken an approach to targeting tumors that is different from other companies," said Dr. Henry Smith, CEO of the company. "While most of cancer research has focused on developing antibodies to specific tumor...

BALTIMORE, June 8 /PRNewswire/ -- Biopharmaceuticals company Gliknik Inc. announced today that the Maryland Health Care Product Development Corporation (MHCPDC) has completed an equity investment in the company. MHCPDC and Gliknik further agreed on June 1, 2010 to undisclosed financial terms, under which the MHCPDC will also make a new equity series investment in Gliknik this summer. The MHCPDC is a supporting organization of the Tech Council of Maryland (TCM). "The MHCPDC board is highly...

NEW YORK, Sept. 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Market for Biosimilars and the Potential for US Follow-on Biologics, The http://www.reportlinker.com/p0137883/World-Market-for-Biosimilars-and-the-Potential-for-US-Follow-on-Biologics-The.html Biosimilars, or generic biologic drugs, are marketed around the world but still restricted in the U.S. This may soon change, and Kalorama Information has released this...

Regulators in Japan on Thursday approved the first-ever generic of a biotech drug.The decision is likely to pave the way "for greater access to high-quality biopharmaceuticals in Japan," according to Sandoz, Novartis AG's generics group.Sandoz' Somatropin injection is used for the treatment of growth hormone deficiency in children as well as growth disruption caused by Turner's syndrome or chronic renal insufficiency, the company said. The drug is being offered as an alternative to Pfizer's...

AMSTERDAM, April 30 /PRNewswire/ -- SynCo Bio Partners B.V. (Amsterdam, The Netherlands), the cGMP manufacturer of clinical and commercial biopharmaceuticals, has won the Vaccine Industry Excellence (ViE) award for Best Contract Manufacturing Organization (CMO) 2009. This award was presented to SynCo at the Washington World Vaccine Congress on the 22nd of April and is a recognition of the excellent work by SynCo's scientists and manufacturing staff on behalf of its clients over the last...

NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus. Glucose is used by...